American College of Cardiology

AUGUST 1, 2024

Can patients with advanced chronic kidney disease (CKD) be initiated on angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARBs) without increasing their risk for needing kidney failure replacement therapy?

ACE Inhibitor 70

ACE Inhibitor Kidney Disease Article 70

Open Heart

APRIL 24, 2024

Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001). were on a beta blocker and on an ACE inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, respectively. and 29.2%, p<0.001).

Heart Failure 52

Heart Failure Preserved Ejection Fraction ACE Inhibitor Pharmacology 52

The British Journal of Cardiology

JULY 17, 2024

2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”

Kidney Disease 52

Kidney Disease Outcomes Diabetes Heart Failure 52

DAIC

APRIL 6, 2024

As evidence has mounted pointing to their benefits in reducing heart failure and other forms of heart disease, researchers have sought to determine whether these drugs could help to prevent heart failure even in people without diabetes or chronic kidney disease.

Heart Attack 98

Heart Attack Heart attacks Heart Failure Outpatient 98

DAIC

APRIL 6, 2024

As evidence has mounted pointing to their benefits in reducing heart failure and other forms of heart disease, researchers have sought to determine whether these drugs could help to prevent heart failure even in people without diabetes or chronic kidney disease.

Heart Attack 81

Heart Attack Heart attacks Heart Failure Outcomes 81